Mitochondrial myopathies are a group of muscle diseases caused by defects in the energy-producing machinery inside cells. Because muscles demand enormous amounts of energy, they are among the first tissues to suffer when mitochondria malfunction. Symptoms range from mild exercise intolerance to profound weakness and drooping eyelids, and they can appear at any age. Diagnosis often requires a combination of blood biomarkers, muscle biopsy, genetic sequencing, and sometimes specialized exercise testing, while treatment remains largely supportive, built around targeted supplements, carefully dosed aerobic exercise, and cardiac monitoring, with several experimental therapies now in clinical trials.
What Goes Wrong at the Cellular Level
Mitochondria generate the bulk of a cell’s energy through a process called oxidative phosphorylation, which depends on a series of protein complexes embedded in the inner mitochondrial membrane. Mitochondrial myopathies arise when genetic mutations, either in the small genome inside the mitochondria themselves or in the nuclear DNA that encodes most mitochondrial proteins, disrupt one or more of these complexes.1PubMed Central. Cardiological manifestations of mitochondrial respiratory chain disorders Skeletal muscle fibers hit hardest by the defect begin to accumulate abnormal mitochondria, lose the ability to generate energy efficiently, and eventually degenerate.
Which complexes are affected depends on the mutation. Patients with large-scale deletions of mitochondrial DNA tend to lose both complex I and complex IV function, with complex IV sometimes hit more severely. Those with nuclear gene defects that lead to the accumulation of multiple smaller deletions often show a more pronounced complex I loss, sometimes without complex IV being involved at all.2Scientific Reports. A novel immunofluorescent assay to investigate oxidative phosphorylation deficiency in mitochondrial myopathy: understanding mechanisms and improving diagnosis These patterns matter because they shape the clinical picture and guide genetic testing.
Common Symptoms
The hallmark of mitochondrial myopathy is exercise intolerance that seems out of proportion to any visible muscle wasting. People tire far more quickly than expected, and recovery after exertion is slow. A person might struggle to walk up a flight of stairs or finish a short jog even though their muscles look relatively normal on examination. This happens because the muscles cannot extract and use oxygen normally during sustained activity, leading to an excessive reliance on less efficient energy pathways and a faster buildup of lactate.3Mitochondrion. Exercise testing as a diagnostic entity in mitochondrial myopathies
Drooping eyelids, called ptosis, is another very common early sign. It often starts on one side and gradually becomes bilateral. In many patients, the muscles that move the eyes also weaken, producing a condition called progressive external ophthalmoplegia, where the eyes lose their full range of motion.4PubMed. Mitochondrial myopathy and ophthalmoplegia in a sporadic patient with the G12315A mutation in mitochondrial DNA Not everyone follows this pattern, though. Some patients develop ptosis and exercise intolerance without any eye-movement problems at all, depending on which mitochondrial DNA variant they carry.5PubMed. A mitochondrial disorder with ptosis and exercise intolerance without ophthalmoparesis secondary to m.5865 T > C variant
Beyond the muscles themselves, fatigue is often the most debilitating complaint. A patient-reported questionnaire developed specifically for this population found that day-to-day fatigue during routine activities was one of the most consistently identified symptoms, often overshadowing the measurable weakness on clinical examination.6PubMed. Development of a Patient-Reported Outcome Questionnaire to Evaluate Primary Mitochondrial Myopathy Symptoms
Recognized Clinical Syndromes
Mitochondrial myopathies are not one disease but a family of overlapping conditions. Certain combinations of symptoms recur often enough that they have been given specific names, though in practice many patients fall somewhere between the textbook categories.
Kearns-Sayre syndrome is one of the best-known. It typically appears before age 20 and involves progressive external ophthalmoplegia, an atypical pigmentary retinopathy affecting the back of the eye, and heart conduction abnormalities that can be life-threatening.7PubMed Central. Kearns-Sayre syndrome: An unusual ophthalmic presentation Patients may also develop muscle weakness, hearing loss, and problems with balance. The syndrome is usually caused by a large deletion in mitochondrial DNA.8PubMed. Kearns-Sayre syndrome with a novel mitochondrial DNA deletion
MERRF (myoclonic epilepsy with ragged-red fibers) and MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) are two other major syndromes. Both affect the brain in addition to muscle, and both can overlap with each other. A single patient can carry features of both syndromes simultaneously, illustrating how blurry the boundaries really are.9Muscle & Nerve. Sporadic MERRF/MELAS overlap syndrome associated with the 3243 tRNALeu(UUR) mutation of mitochondrial DNA
Cardiac Involvement
The heart is a muscle, and it too depends heavily on mitochondria. Cardiac problems are common enough in mitochondrial myopathies that routine heart screening is considered essential. The specific type of heart involvement varies by mutation. In a study of 17 patients with documented mitochondrial DNA defects, all three patients with Kearns-Sayre syndrome had heart conduction disturbances, and among those with MERRF, two of three had enlarged hearts with abnormal wall motion. Patients with MELAS more often showed thickening of the heart’s left ventricle.10PubMed. Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects
A larger study following nearly 600 adults with mitochondrial diseases found that about 5% developed heart failure and another 5% experienced serious arrhythmias over roughly seven years. The m.3243A>G variant, one of the most common pathogenic mutations, carried a more than fourfold increased risk of heart failure. Large-scale mitochondrial DNA deletions were a strong predictor of dangerous rhythm disturbances.11PubMed. Cardiac Outcomes in Adults With Mitochondrial Diseases These findings underscore why regular electrocardiograms and echocardiograms are standard care, even in patients whose main complaint is skeletal muscle weakness.
How Diagnosis Works
Diagnosing a mitochondrial myopathy can be frustratingly slow, in part because the symptoms overlap with many other conditions. The process typically involves several complementary approaches rather than any single definitive test.
Blood Biomarkers
Traditional blood tests look for elevated lactate, but lactate is not very specific; it can rise after exercise, stress, or other illnesses. Two newer protein biomarkers, GDF-15 and FGF-21, have shown much better diagnostic accuracy. In adults, GDF-15 had a higher diagnostic odds ratio than FGF-21 and outperformed it on sensitivity, correctly identifying roughly 78% of patients with mitochondrial disease.12PubMed Central. A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases In children, however, GDF-15 levels can rise in a range of non-mitochondrial disorders, limiting its usefulness. In pediatric patients, FGF-21 appears to be the better standalone marker, with good ability to distinguish mitochondrial disease from other conditions.13PubMed. FGF21 outperforms GDF15 as a diagnostic biomarker of mitochondrial disease in children Another pediatric study found GDF-15 had perfect specificity (100%) at its optimal cutoff, but its sensitivity was lower, catching about three-quarters of cases.14PubMed Central. Circulating FGF21 and GDF15 as Biomarkers for Screening, Diagnosis, and Severity Assessment of Primary Mitochondrial Disorders in Children The picture that emerges is that neither marker alone is a slam dunk, but either can help justify moving on to more invasive testing.
Muscle Biopsy
Muscle biopsy has long been a cornerstone of diagnosis. Pathologists look for so-called ragged-red fibers, muscle fibers packed with swollen, abnormal mitochondria that stain bright red with a special dye. These fibers are a major diagnostic hallmark of mitochondrial myopathy in both children and adults.15PubMed Central. Automatic Recognition of Ragged Red Fibers in Muscle Biopsy from Patients with Mitochondrial Disorders Additional staining for cytochrome c oxidase (complex IV) can reveal fibers that have lost this enzyme’s activity, appearing as pale patches against normally stained tissue. The pattern of ragged-red fibers combined with cytochrome c oxidase-negative fibers gives clinicians strong circumstantial evidence of a mitochondrial defect.9Muscle & Nerve. Sporadic MERRF/MELAS overlap syndrome associated with the 3243 tRNALeu(UUR) mutation of mitochondrial DNA
One important caveat: ragged-red fibers are not unique to primary mitochondrial disease. They can also appear in inflammatory muscle conditions like inclusion body myositis and dermatomyositis. When they show up in those settings, they tend to predict a poor response to immune-suppressing drugs, suggesting that the mitochondrial dysfunction is contributing to the problem independently of inflammation.16PubMed Central. Mitochondrial pathology in immune and inflammatory myopathies
Genetic Testing
Sequencing mitochondrial DNA and relevant nuclear genes has become increasingly accessible and can provide a definitive molecular diagnosis. A tricky aspect of mitochondrial genetics is heteroplasmy, where normal and mutant copies of mitochondrial DNA coexist within the same cell, and the proportion of mutant copies can vary dramatically between tissues. A patient’s blood might carry only 5% mutant mitochondrial DNA while the same mutation sits at 70% in muscle tissue.17PubMed Central. Tissue-specific mitochondrial DNA, MT-TF, pathogenic variants in mitochondrial myopathies This means a normal result on a blood test does not rule out the diagnosis. When suspicion remains high, sequencing DNA from a muscle biopsy sample can catch mutations that blood-based testing misses.
Exercise Testing
Formal cardiopulmonary exercise testing can serve as a noninvasive screening tool. People with mitochondrial myopathy show characteristically low peak oxygen consumption, inefficient oxygen use, and an exaggerated heart rate and ventilatory response relative to the work being performed.3Mitochondrion. Exercise testing as a diagnostic entity in mitochondrial myopathies A novel algorithm using metrics like oxygen uptake efficiency slope and the ratio of oxygen consumption to workload showed excellent ability to distinguish mitochondrial myopathy patients from healthy controls in one study.18PubMed. A novel exercise testing algorithm to diagnose mitochondrial myopathy Exercise testing is not definitive on its own, but it can flag who should go on to more invasive workup and can track disease progression over time.
Supplements and Pharmacological Approaches
There is no drug that cures mitochondrial myopathy, and the evidence base for most pharmacological treatments is thinner than patients or their families would hope. That said, a core group of supplements is widely used. Coenzyme Q10 (or its more bioavailable form, ubiquinol), L-carnitine, and riboflavin (vitamin B2) are the most common, and most patients take four or more supplements simultaneously.19PubMed Central. Mitochondrial disease patients’ perception of dietary supplements’ use The rationale is biochemical: these compounds participate in mitochondrial energy production or scavenge damaging byproducts. Many clinicians have observed meaningful improvements in individual patients, and patient surveys report perceived benefits within a few weeks to three months, with a low rate of side effects. Still, rigorous proof that these supplements change the long-term course of the disease is lacking.20PubMed Central. A modern approach to the treatment of mitochondrial disease
One concern worth noting: clinical data have suggested that L-carnitine may accelerate atherosclerotic disease through its metabolism by gut bacteria into compounds that promote plaque formation.21PubMed Central. Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines This does not mean patients should stop taking it unilaterally, but it is the kind of risk-benefit conversation worth having with a specialist, especially for people on long-term supplementation.
Exercise as Therapy
It might seem counterintuitive to prescribe exercise for a disease defined by exercise intolerance, but aerobic training is one of the most clearly supported interventions. A study of 20 patients with various mitochondrial DNA mutations put them through 12 weeks of cycling, three to four sessions per week at moderate intensity. Peak oxygen uptake improved by about 26%, and a key enzyme involved in mitochondrial energy production increased by roughly 67% in muscle tissue. The amount of mitochondrial DNA in muscle rose by 81%, an increase not seen in the healthy control subjects, suggesting the training may specifically stimulate mitochondrial proliferation in affected tissue. No adverse events occurred.22PubMed. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy
The key practical point is that exercise programs should start at low intensity and progress gradually. A reasonable starting place is moderate-effort cycling or walking at around 60–70% of a person’s maximum capacity, with sessions of 20–30 minutes. Supervision early on helps calibrate intensity and catch any warning signs.
Experimental Therapies
Several newer approaches are moving through the research pipeline. Elamipretide is a synthetic peptide designed to stabilize the inner mitochondrial membrane. In a randomized crossover trial of adults with primary mitochondrial myopathy, participants treated with elamipretide reported significantly less fatigue during daily activities compared to placebo. The improvement in six-minute walk distance was modest and did not reach conventional statistical significance, but the fatigue findings were considered clinically meaningful.23PubMed Central. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy The same drug is also being tested in Barth syndrome, a genetic disorder of mitochondrial membrane composition.24Genetics in Medicine. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism
Nicotinamide riboside, a form of vitamin B3 that boosts levels of the coenzyme NAD+, has shown striking results in mouse models of mitochondrial myopathy. Treated mice experienced delayed disease progression, reduced formation of mitochondrial DNA deletions, and robust stimulation of new mitochondria in skeletal muscle.25PubMed Central. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3 In a clinical case involving a patient with a different mitochondrial defect (ACAD9 deficiency), combining nicotinamide riboside with bezafibrate, a drug that activates a mitochondrial biogenesis pathway, temporarily stabilized cardiomyopathy and lactic acidosis.26PubMed Central. ACAD9 treatment with bezafibrate and nicotinamide riboside temporarily stabilizes cardiomyopathy and lactic acidosis Larger human trials are still needed to know whether these benefits translate broadly.
On the gene therapy front, engineered nucleases that are targeted specifically to mitochondria, such as mitoTALENs and mitoZFNs, have been used in human cells and in a mouse model to selectively destroy copies of mitochondrial DNA carrying pathogenic mutations. By shifting the ratio of mutant to normal DNA, these tools could theoretically correct the underlying genetic defect.27PubMed Central. Mitochondrial DNA heteroplasmy in disease and targeted nuclease-based therapeutic approaches This work remains preclinical, but it represents one of the most conceptually direct routes to a cure.
Dietary Experiments
A ketogenic diet, very high in fat and very low in carbohydrates, has attracted attention based on cell-culture work suggesting it might select against cells harboring mutant mitochondrial DNA. In a mouse model of mitochondrial myopathy, the diet reduced the number of cytochrome c oxidase-negative muscle fibers, prevented the characteristic ultrastructural abnormalities, and normalized widespread metabolic changes. It did not significantly alter the amount or quality of mitochondrial DNA itself but appeared to stimulate the production of new mitochondria.28Human Molecular Genetics. Ketogenic diet slows down mitochondrial myopathy progression in mice Proper patient trials have not been completed, so the diet is not a standard recommendation. Anyone considering it should work with a metabolic specialist, because fasting and severe carbohydrate restriction can themselves stress mitochondrial function if not carefully managed.
Drugs That Can Make Things Worse
Certain commonly prescribed medications are known to interfere with mitochondrial function, and their use in people with mitochondrial myopathy requires caution. Valproic acid, an antiseizure drug, and aminoglycoside antibiotics are well-established offenders and are generally avoided entirely.29PubMed Central. Drug safety in patients with mitochondrial disease: an observational cohort study Other drugs have theoretical concerns based on laboratory data but less clear clinical evidence of harm. In one observational study of 44 mitochondrial disease patients, more than half were taking ibuprofen, about a quarter were on beta-blockers, and roughly a fifth were using statins, all of which have been flagged as potentially problematic for mitochondrial function in preclinical studies. No aminoglycosides or valproic acid were used in that cohort, reflecting how seriously clinicians take those particular risks.29PubMed Central. Drug safety in patients with mitochondrial disease: an observational cohort study The practical takeaway is that patients should keep an updated medication list and ensure every prescribing doctor knows about their mitochondrial diagnosis. Monitoring with bloodwork including creatine kinase and lactate levels is advisable when starting any new medication.30PubMed Central. Mitochondrial disorders and drugs: what every physician should know
Anesthesia and Surgery
Surgery poses unique risks for people with mitochondrial myopathies, and anesthesiologists need to know about the diagnosis well in advance. All general anesthetics interfere with mitochondrial energy pathways to some degree. Patients with mitochondrial disease tend to be more sensitive to volatile anesthetics, and propofol, though widely used, disrupts mitochondrial function through multiple mechanisms and should be used cautiously. Succinylcholine, a muscle relaxant, is contraindicated because of risks of dangerously high potassium levels. Non-depolarizing muscle relaxants can be used, but their effects are unpredictable in this population.31PubMed. Anesthetic Management of the Patient with Mitochondrial Disease: A Review of Current Best Evidence
One common worry is malignant hyperthermia, a dangerous overheating reaction sometimes triggered by certain anesthetics. Fortunately, mitochondrial disease does not increase this risk, despite the superficial similarities. The greater concern is prolonged fasting before surgery, which pushes the body into a catabolic state that stresses an already impaired energy system, along with inadequate pain control afterward, which can prolong metabolic stress.32PubMed Central. Anesthetic considerations in patients with mitochondrial defects Preoperative planning should include intravenous glucose to avoid prolonged fasting and close metabolic monitoring throughout recovery.
Preventing Transmission to Children
Because the most common mitochondrial myopathies involve mutations in mitochondrial DNA, which is inherited exclusively from the mother, women who carry pathogenic variants face a real risk of passing the disease to their children. Mitochondrial replacement therapy is a specialized form of in vitro fertilization that attempts to prevent this. The basic idea is to take the mother’s nuclear DNA (which carries her personal traits) and transfer it into a donor egg whose healthy mitochondria replace the mother’s defective ones. Techniques include spindle transfer and pronuclear transfer.33Heliyon. Development of mitochondrial replacement therapy: A review
Clinical cases using both principal methods have now been reported, but recent data continues to raise questions about reliability. In some cases, small amounts of mutant mitochondrial DNA carried over from the mother’s egg have expanded in the resulting embryo, potentially reintroducing the very disease the procedure aimed to prevent.34PubMed. Revisiting the promise and pitfalls of mitochondrial replacement therapies The technique remains legal in only a handful of countries and is still considered experimental. For families weighing reproductive options, preimplantation genetic testing of conventionally conceived embryos is a more established, though imperfect, alternative.
Why Mitochondrial Maintenance Matters
Mitochondria are not static organelles. They constantly fuse together and split apart in a process called mitochondrial dynamics, and this remodeling is essential for keeping them healthy. Fusion allows damaged mitochondria to share contents with healthy neighbors, maintaining the energy reserve needed for sustained muscle contraction. When fusion is disrupted, such as through loss of a key protein called Mfn1, the metabolic reserve drops and calcium signaling during prolonged muscle stimulation falls apart.35PubMed Central. Mitochondrial fusion is frequent in skeletal muscle and supports excitation-contraction coupling On the fission side, proteins that drive mitochondrial splitting are dramatically reduced in certain congenital muscular dystrophies linked to mitochondrial enlargement.36Scientific Reports. Reduced mitochondrial fission and impaired energy metabolism in human primary skeletal muscle cells of Megaconial Congenital Muscular Dystrophy Therapies that can restore normal mitochondrial turnover, whether through exercise, NAD+ boosting compounds, or future drugs, may prove as important as targeting the genetic defect itself.